News
SAN DIEGO
BioTech

DexCom cited as bellwether

By Daily Transcript staff report

Friday, May 16, 2014

CNBC stock commentator Jim Cramer on Friday cited San Diego’s DexCom Inc. (Nasdaq: DXCM) as a bellwether for the stock market, which should go into a turnaround on Wall Street within the next year.

To continue reading, subscribe now
or
log in to your account

User Response

Dexcom Inc.

Company Website

5555 Oberlin Drive
San Diego, CA 92121

Company Trade Data

Stock Symbol

Change
Chg	%Chg

Volume

52-Week
High	Low

DXCM

59.78

-1.22

- 2.00%

488,855,000

63.56

28.09

Insider Trade Data

Date	Insider	Shares	Type	Value
01/26/2015	Pacelli, Steven Robert	24,532	Sell	$1,463,812
01/26/2015	Pacelli, Steven Robert	24,532	Exchange	$228,388
01/26/2015	Balo, Andrew K	15,001	Sell	$888,739
01/26/2015	Balo, Andrew K	15,001	Exchange	$125,303
01/20/2015	Moy, Jeffrey C	5,000	Sell	$287,906

Dexcom Inc. Executive(s):

Terrance Gregg

Chief Executive Officer, Director

Kevin Sayer

Director, President

Patrick Murphy

Assist. General Counsel

Dexcom, Asante Solutions agree to data integration - (8-7-2014)
Dexcom gains FDA approval; stocks rise - (6-3-2014)
DexCom cited as bellwether - (5-16-2014)
Zacks picks Qualcomm, DexCom for growth - (3-24-2014)
FDA OKs pediatric use of DexCom's glucose monitoring system - (2-4-2014)
DexCom climbs on strong 3Q sales, outlook - (11-7-2013)

Similar Companies

NAICS - -

Other Lists

2014

Biomed & Biotech Firms - Publicly Traded*

Subscribe | Log In

Subscribe Today!